[chamada] National Institutes of Health (NIH) – Gene Fusions in Pediatric Sarcomas (R01 and R21)

14/09/2017 15:21

Objetivo:
The overall goal of this funding opportunity announcement (FOA) is to encourage the submission of research grant applications to investigate the molecular mechanisms by which oncogenic fusion genes and their gene products contribute to pediatric sarcoma initiation, progression, and metastasis. Better understanding of the molecular pathways activated by chromosomal translocations in pediatric sarcomas, and their relationship to oncogenesis and tumor progression, can elucidate mechanisms of cancer pathogenesis and potentially lead to novel therapeutics.

Inscrições:
R01: October 05, 2017;
R21: October 16, 2017.

Letter of Intent Due Date(s):
30 days prior to the application due date.

Data de expiração:
May 8, 2020.

Mais informações em R01 R21.

Tags: BolsaEditalExteriorNIH

[chamada] National Institutes of Health (NIH) – Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01)

14/09/2017 15:18

Objetivo:
The Funding Opportunity Announcement (FOA) invites research grant applications from organizations/institutions that propose the development of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in human brain, and that incorporate pilot or clinical feasibility evaluation in pre-clinical studies, model development, or clinical studies.

Inscrições:
R01: October 05, 2017.

Letter of Intent Due Date(s):
30 days prior to the application due date.

Data de expiração:
September 8, 2019.

Mais informações no site.

Tags: BolsaEditalExteriorNIH

[chamada] National Institutes of Health (NIH) – Eradication of HIV-1 from Central Nervous system Reservoirs (R01)

14/09/2017 15:14

Objetivo:
The Funding Opportunity Announcement (FOA) invites research grant applications studying mechanisms of HIV-1 persistence and eradication strategies specifically focused on the central nervous system (CNS) in the context of viral suppression. Basic and translational research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required.

Inscrições:
R01: October 05, 2017.

Letter of Intent Due Date(s):
30 days prior to the application due date.

Data de expiração:
January 8, 2020.

Mais informações no site.

Tags: BolsaEditalExteriorNIH

[chamada] NIH – Research on Autism Spectrum Disorders (R01, R03 and R21)

13/09/2017 18:07

Objetivo:
The purpose of the Funding Opportunity Announcement (FOA) is to encourage research grant applications to support research designed to elucidate the etiology, epidemiology, diagnosis, treatment, and optimal means of service delivery in relation to Autism Spectrum Disorders (ASD).

Inscrições:
R01: October 05, 2017;
R03 and R21: October 16, 2017.

Letter of Intent Due Date(s):
30 days prior to the application due date.

Data de expiração:
September 8, 2019.

Mais informações em R01, R03 e R21.

Tags: BolsaEditalExteriorNIH

[chamada] NIH – Potential Effects of Metformin on Aging and Age-Related Conditions: Small-Scale Clinical Studies and Secondary Analysis of Controlled Clinical Studies (R01)

13/09/2017 17:10

Objetivo:
Data from clinical studies of metformin in a variety of patient populations suggest that it may have other effects, besides being an antihyperglycemic agent, which warrant further attention in translational aging research. The objective of the Funding Opportunity Announcement (FOA) is to support research projects (R01), including small-scale physiologic studies in humans or secondary analyses of data and/or stored biospecimens from controlled clinical intervention studies, to increase the understanding of the clinical translational potential of metformin to delay deleterious aging changes or to extend healthy human life span. This includes identification of specific populations particularly likely to benefit from treatment, and/or obtaining information on metformins human physiologic and cellular effects that would be useful in identifying novel molecular targets.

Inscrições:
R01: October 05, 2017.

Letter of Intent Due Date(s):
30 days prior to the application due date.

Data de expiração:
May 8, 2020.

Mais informações no site.

Tags: BolsaEditalExteriorNIH

[chamada] NIH – Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 and R21)

13/09/2017 17:05

Objetivo:
The Funding Opportunity Announcement (FOA) encourages research grant applications directed toward developing next-generation human cell-derived microphysiological systems (MPS) with improved fidelity to complex human brain, spinal, peripheral nervous system and/or sensory end organ circuit physiology in vivo, which will ultimately facilitate analysis of higher order functional deficits relevant to complex nervous system disorders.

Inscrições:
R01: October 05, 2017;
R21: October 16, 2017.

Letter of Intent Due Date(s):
30 days prior to the application due date.

Data de expiração:
January 8, 2020.

Mais informações em R01, R21.

Tags: BolsaEditalExteriorNIH

[chamada] NIH – NLM Express Research Grants in Biomedical Informatics (R01)

13/09/2017 17:00

Objetivo:
The National Library of Medicine (NLM) offers support for innovative research in biomedical informatics and data science. The scope of NLM s interest in the research domain of informatics is broad and interdisciplinary, developing methods and approaches in biomedical computing, data science and related information fields for application domains of health and biomedicine, including health care delivery, basic biomedical research, clinical and translational research, precision medicine, public health, biosurveillance, health information management in disasters, and similar areas. NLM defines biomedical informatics as the science of optimal representation, organization, management, integration and presentation of information relevant to human health and biology, for purposes of learning, sharing and use.

Inscrições:
R01: October 05, 2017.

Letter of Intent Due Date(s):
30 days prior to the application due date.

Data de expiração:
September 8, 2019.

Mais informações no site.

Tags: BolsaEditalExteriorNIH

[chamada] NIH – Improving Individual and Family Outcomes Through Continuity and Coordination of Care in Hospice (R01 and R21)

11/09/2017 15:57

Objetivo:
The funding opportunity announcement (FOA) seeks to stimulate research that focuses on reducing negative individual and family outcomes related to unwanted transitions at the end of life and optimizing the individual and family utcomes related to high quality coordination of care of care of individuals who are enrolled in hospice. This FOA emphasizes individuals who are receiving hospice care and their family caregivers, in any setting where hospice care is provided, including their home, a relative’s home, a hospice inpatient facility, an assisted living facility, a short- or long-term care facility, or a hospital.

Inscrições:
R01: October 05, 2017;
R21: October 16, 2017.

Letter of Intent Due Date(s):
30 days prior to the application due date.

Data de expiração:
January 8, 2020.

Mais informações em R01 e R21.

Tags: EditalExteriorNIH

[chamada] NIH – NIBIB Exploratory/Developmental Research Grant Program (R21)

11/09/2017 15:50

Objetivo:
The Funding Opportunity Announcement (FOA) will support exploratory/developmental research programs of interest to the National Institute of Biomedical Imaging and Bioengineering (NIBIB). These studies are expected to lead to breakthroughs in development of innovative techniques, agents, methodologies, models, or their applications. These studies may involve considerable risk that should be balanced by the potential high impact on human-health and related research. Applicants are expected to propose novel biomedical research approaches for which there is no preliminary data to demonstrate the feasibility of the proposed project. A project may be exploratory, developmental, proof of concept, or high risk-high impact, and may be technology design-directed, discovery-driven, or hypothesis-driven.

Inscrições:
R21: October 16, 2017.

Letter of Intent Due Date(s):
30 days prior to the application due date.

Data de expiração:
September 8, 2020.

Mais informações no site.

Tags: EditalExteriorNIH

[chamada] NIH – The Interplay of Cell Death Pathways in Cancer Cell Survival and Resistance to Therapy (R01 and R21)

11/09/2017 15:46

Objetivo:
The purpose of the funding opportunity announcement (FOA) is to stimulate research in the interplay between cell death pathways in naïve and drug resistant cancers. Regulated cell death, especially apoptosis and necroptosis, are natural barriers that restrict malignant cells from surviving and disseminating. Evasion of cell death mechanisms is one of the hallmarks of cancer contributing to tumor progression, metastases and resistance to therapy. Recent studies show that the machinery to activate different forms of cell death coexists in cells but the crosstalk of cell death pathways in cancer has not been systematically studied. Research into the intersection of cell death programs will allow for better defining markers of cell death pathway at the molecular level and offers the possibility that the specific mediators of cell survival may be inhibited and/or the mediators of cell death enhanced, driving naïve and drug resistant cancer cells toward effective cell death.

Inscrições:
R01: October 05, 2017;
R21: October 16, 2017.

Letter of Intent Due Date(s):
30 days prior to the application due date.

Data de expiração:
September 8, 2020.

Mais informações em R01 e R21.

Tags: EditalExteriorNIH